Institutional members access full text with Ovid®

Share this article on:

Current Status of Parkinsonism-Related Adverse Events and Associated Drugs in Korea

Kim Siin PharmD; Suh, Hae Sun PhD
Journal of Patient Safety: Post Author Corrections: April 01, 2017
doi: 10.1097/PTS.0000000000000373
Original Article: PDF Only


The aim of the study was to explore the current status of drug-induced parkinsonism and drugs possibly related to drug-induced parkinsonism in Korea.


We conducted a cross-sectional study using the Korea Adverse Event Reporting System database between July 1, 2010, and June 30, 2015. We identified all adverse event reports associated with parkinsonism.


There were 1402 adverse event reports associated with parkinsonism. The number of adverse event reports has increased annually. Among the 1499 drugs associated with parkinsonism, the most common were metoclopramide (49.77%) and paliperidone (16.14%). The major therapeutic groups (the third level of the Anatomical Therapeutic Chemical code) were propulsives (53.87%) and antipsychotics (35.58%). The mean time of onset of parkinsonism was 34.9 days. However, the time of onset of parkinsonism varied by drug, for example, it was 4.6 days for metoclopramide and 37.2 days for paliperidone.


Metoclopramide and antipsychotics were reported in most adverse event reports associated with parkinsonism in Korea.

Correspondence: Hae Sun Suh, PhD, 2, Busandaehak-ro 63 beon-gil, Geumjeong-gu, Busan 609-735, South Korea (e-mail:

The authors disclose no conflict of interest.

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2016R1C1B1009198).

This study was exempt from an ethical review by the Pusan National University Institutional Review Board (PNU IRB/2016_29_HR).

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved